AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04000204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane
Description: 60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
Study NCT02459678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
Study NCT01093911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP7657
Description: Ascending single doses of CDP7657
Study NCT01093911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.9% sodium chloride aqueous solution
Study NCT01586819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete.
Study NCT01586819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Peel Only
Description: After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
Study NCT01559012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clonidine
Description: transdermal clonidine patch 5 mg q. 5 days
Study NCT03584087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: TG 0 (0Hr)
Study NCT04520321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (placebo)
Description: Placebo
Study NCT01177540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
Study NCT01177540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
Study NCT03390881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting condition
Description: Subjects will fast over the whole experimental period (480 min)
Study NCT03390881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar condition
Description: After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
Study NCT04979702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
Study NCT03390881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat condition
Description: After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
Study NCT00648596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
Study NCT00648596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Study NCT01571895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2156A
Description: DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
Study NCT01442870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study NCT04979702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth technology assisted exercise counselling
Description: Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
Study NCT03824743 — intervention group
Intervention type: DRUG
Intervention: Lactate Ringer
Description: Patients managed with Lactate Ringer and obstetric hemorrhage
Study NCT03824743 — intervention group
Intervention type: DRUG
Intervention: Plasma-lyte
Description: Patients managed with Plasma-Lyte and obstetric hemorrhage
Study NCT03584087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Duration of Terlipressin after EVL
Study NCT00047112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT04083807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TISSEEL Lyo
Description: The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
Study NCT04083807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression with surgical gauze pads
Description: Surgical 4x4 inches gauze pads
Study NCT02919527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Myofascial-Release
Description: Self-Myofascial-Release performed at the anterior thigh
Study NCT02919527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Static Stretching performed at the anterior thigh
Study NCT02819791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized conventional therapy alone
Description: Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
Study NCT02819791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized conventional therapy alone
Description: Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
Study NCT02819791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized conventional therapy with therapeutic education
Description: The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress.
Study NCT03172572 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive pancreatoduodenectomy
Description: Laparoscopic, robot-assisted, or hybrid resection
Study NCT03172572 — intervention group
Intervention type: PROCEDURE
Intervention: Open pancreatoduodenectomy
Description: Open resection
Study NCT03706183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia-modified albumin
Description: The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
Study NCT03706183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing thresholds
Description: The hearing levels will be determined for each group.
Study NCT00554372 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
Study NCT01797913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
Study NCT02171741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: continuous daily dosing for 20 or 13 days
Study NCT02171741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: single infusion on day 1
Study NCT03524638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visbiome
Description: Colorectal surgery plus administration of Visbiome on post-operative day 2.
Study NCT03524638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Surgery
Description: Colorectal surgery alone
Study NCT04115670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group of educational intervention on the neurophysiology of pain and physical exercises
Description: The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week.
Study NCT04115670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will follow its normal course of activity
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
Study NCT02819687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Study NCT03854422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left position
Description: colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
Study NCT03854422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left supine position
Description: Colonoscopy in the Left supine position
Study NCT03854422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic position
Description: Colonoscopy in the Dynamic position
Study NCT03821493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 10 mg tablets
Description: On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole.
Study NCT03821493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Solution 200 mg
Description: Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets.
Study NCT01017237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
Study NCT01017237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
Study NCT01017237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
Study NCT02064881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin glycinate
Description: All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
Study NCT02064881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
Study NCT01334203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine
Description: Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.
Study NCT01334203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.
Study NCT00047112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT05697887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
Study NCT02790970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PReDicT Test
Description: PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
Study NCT02790970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
Study NCT01983579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular anti-VEGF injection
Study NCT01983579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study NCT01531387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
Study NCT03569332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alarm
Description: 1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied.
Study NCT03569332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse's dashboard
Description: 1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display.
Study NCT04391387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prone position
Description: a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
Study NCT04391387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
Study NCT03532620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin Calcium
Description: In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.
Study NCT03532620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.
Study NCT04166838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 UCARTcells
Description: This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
Study NCT00047112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00047112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00047112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00047112 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02454855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.
Study NCT02819687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02921087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Test Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days
Study NCT02921087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control Daily Disposable Soft Contact Lenses
Description: Worn daily for 7 +/- 2 days
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: intravenous, 375 mg/m2, day 1
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab: intravenous, 375 mg/m2, day 1
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Study NCT02484482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Study NCT06446791 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mehri Turki Surgical Technique of the Webbed Neck
Description: The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
Study NCT02505113 — intervention group
Intervention type: DRUG
Intervention: Montelukast
Description: Montelukast (10mg, q.d., p.o.)
Study NCT03701919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin pyloroplasty
Description: Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
Study NCT02027324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol group
Description: 2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
Study NCT03701919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline pyloric injection
Description: Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
Study NCT01160913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound infusion